ArticleInfluenza and other respiratory viruses2026
Severity and Cost of Respiratory Syncytial Virus Versus Influenza in Hospitalized Adults in Spain.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Severity and Cost of Respiratory Syncytial Virus Versus Influenza in Hospitalized Adults in Spain.Influenza and other respiratory viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) can lead to severe outcomes, particularly in older and vulnerable adults, yet it remains underdiagnosed due to limited testing. This study compared the severity and costs of laboratory-confirmed RSV versus influenza hospitalizations.
methodsWe performed a retrospective analysis using data from the Valencia Hospital Network for the Study of Infectious Diseases (VAHNSI), covering up to 46% of the Valencia Region's population. Hospitalized influenza-like illness (ILI) cases in individuals aged ≥ 65 years across six seasons (2014/15-2019/20) were included. RSV and influenza were identified by multiplex RT-PCR. Outcomes assessed included mechanical ventilation (MV), hospital length of stay (LOS), in-hospital death, 30-day post-discharge death, and hospitalization costs. Logistic and log-normal regression models were used to compare severity and cost outcomes between RSV and influenza, adjusting for age, sex, comorbidities, and influenza vaccination status. Odds ratios (ORs) and mean ratios (MRs) with 95% confidence intervals (CIs) were calculated.
resultsOf 1954 hospitalizations, 429 (22%) were due to RSV and 1525 (78%) to influenza. RSV cases showed higher MV use (9.26% vs. 4.15%; adjusted OR 2.43 [95% CI: 1.61-3.67]) and longer LOS (7.7 vs. 6.8 days; adjusted MR 1.10 [95% CI: 1.02-1.19]). Mortality outcomes were similar. RSV hospitalizations incurred 6% higher mean costs (€3907 vs. €3806).
conclusionsRSV hospitalizations in older adults were less frequent but more severe and costly than influenza, with comparable mortality. These findings highlight the importance of RSV prevention and support the development of targeted vaccination programs for the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.